Key Takeaways
- •PIE (post-inflammatory erythema) appears as red or purple marks — it's vascular, not pigment-related.
- •PIH (post-inflammatory hyperpigmentation) appears as brown or dark marks — it's caused by excess melanin.
- •The glass test: press a clear glass against the mark. If it disappears, it's PIE. If it stays, it's PIH.
- •PIE responds to vascular treatments (time, azelaic acid, certain lasers); PIH responds to tyrosinase inhibitors.
- •Both types are worsened by sun exposure, making SPF critical for resolution.
- •PIE is more common in lighter skin tones; PIH is more common in darker skin tones.
What's Actually Happening in Your Skin
When your skin experiences inflammation — from acne, a wound, or any other inflammatory event — the healing process can leave behind visible marks that linger long after the original lesion has resolved. These marks are broadly categorized as post-inflammatory changes, but they come in two fundamentally different forms with distinct underlying mechanisms.
Post-inflammatory erythema (PIE) is caused by damage to the small capillaries and blood vessels in the dermis during the inflammatory process. The damaged blood vessels dilate and become more visible through the skin, creating red, pink, or purple marks. PIE is not a pigmentation disorder — there is no excess melanin involved. It's a vascular phenomenon.
Post-inflammatory hyperpigmentation (PIH) occurs when inflammation triggers melanocytes to overproduce melanin, which is then deposited in the epidermis or dermis. The excess melanin creates brown, dark brown, or grayish patches at the site of the original inflammation. PIH is a true pigmentary disorder affecting the melanin production pathway.
How to Distinguish PIE from PIH
The simplest diagnostic test is the diascopy or glass test. Press a clear glass or transparent plastic firmly against the mark. If the mark disappears or fades significantly under pressure, it's PIE — you're briefly compressing the dilated blood vessels, blanching the redness. If the mark remains visible under pressure, it's PIH — the melanin deposits don't move when blood is displaced.
Color is another useful indicator. PIE tends to present as bright red, pink, or purple-red marks, especially visible in lighter skin tones (Fitzpatrick I-III). PIH presents as tan, brown, dark brown, or sometimes grayish marks, and is more prevalent and persistent in darker skin tones (Fitzpatrick IV-VI).
It's possible — and common — to have both PIE and PIH simultaneously, especially after severe acne. An initially red mark (PIE) can develop brownish pigmentation (PIH) around or beneath it as the healing process progresses. In these mixed cases, treatment should address both components.
Treating PIE: The Vascular Marks
PIE is frustratingly slow to resolve because damaged capillaries must repair themselves naturally. There is no topical ingredient that directly speeds up capillary repair. However, several approaches can help manage PIE and support the healing process.
Azelaic acid at 15-20% is one of the most effective topical options for PIE. It has both anti-inflammatory and mild vascular-modulating properties that can reduce the redness associated with PIE. It's also excellent for preventing new PIE from forming by reducing the severity of acne-related inflammation.
Time and sun protection are the two most important factors for PIE resolution. UV exposure causes vasodilation that worsens the appearance of PIE and slows healing. Rigorous SPF 30+ use accelerates the fading process significantly. In-office treatments like vascular lasers (pulsed dye laser, KTP laser) can dramatically accelerate PIE resolution but require multiple sessions.
Treating PIH: The Melanin Marks
PIH is more responsive to topical treatment because we have effective ingredients that target multiple steps of the melanin production pathway. The gold standard remains hydroquinone at 2-4%, which inhibits tyrosinase — the enzyme responsible for converting tyrosine to melanin. It's effective but should be used under dermatological supervision, especially at prescription strengths.
Over-the-counter alternatives include vitamin C (ascorbic acid at 10-20%), which inhibits tyrosinase and provides antioxidant protection; niacinamide (4-5%), which blocks melanosome transfer from melanocytes to keratinocytes; alpha arbutin, a gentler tyrosinase inhibitor; and tranexamic acid, which interrupts the UV-stimulated melanogenic pathway.
Retinoids accelerate the resolution of PIH by increasing epidermal turnover, physically moving pigmented keratinocytes to the surface faster. Combining a retinoid with a tyrosinase inhibitor addresses PIH from both ends — reducing new melanin production while clearing existing pigmented cells more rapidly. AHAs like glycolic acid complement this by providing additional exfoliation.
The Critical Role of Sun Protection
No treatment for PIE or PIH will be maximally effective without rigorous sun protection. UV radiation stimulates melanogenesis (worsening PIH), causes vasodilation (worsening PIE), and triggers inflammatory pathways that can perpetuate both conditions. Using brightening serums without sunscreen is like bailing water while leaving the faucet running.
Use a broad-spectrum SPF 30 or higher every day, regardless of weather or season. UV radiation penetrates clouds and windows. Reapply every two hours during prolonged sun exposure. Tinted sunscreens with iron oxide provide additional protection against visible light, which has been shown to contribute to hyperpigmentation, particularly in darker skin tones.
Sun-protective behaviors beyond sunscreen — seeking shade, wearing hats, avoiding peak UV hours — significantly impact the speed at which post-inflammatory marks resolve. Patients who are diligent about sun protection consistently show faster and more complete resolution of both PIE and PIH.
What to Avoid
Picking, squeezing, or irritating existing acne lesions dramatically increases the risk and severity of both PIE and PIH. The additional trauma extends inflammation deeper and wider, damaging more capillaries (causing PIE) and stimulating more melanocytes (causing PIH). The most effective strategy for preventing post-inflammatory marks is minimizing the inflammation itself.
Over-exfoliation while trying to treat PIH can backfire by triggering additional inflammation that produces new hyperpigmentation. If you're using multiple brightening and exfoliating actives simultaneously and your skin is red, irritated, or stinging, you're likely causing more pigmentation than you're resolving.
Be cautious with aggressive in-office treatments on darker skin tones. Some lasers, chemical peels, and microdermabrasion treatments that work beautifully on lighter skin can trigger paradoxical hyperpigmentation in Fitzpatrick types IV-VI. Always consult a dermatologist experienced with diverse skin tones before pursuing in-office treatments for PIH.
Realistic Timelines
Epidermal PIH (the more superficial form) typically resolves within 3-12 months with appropriate treatment and sun protection. Dermal PIH (deeper melanin deposition, often appearing grayish) can persist for years and is more resistant to topical treatment. A dermatologist can assess the depth of your PIH using a Wood's lamp examination.
PIE timelines are highly variable. Mild PIE from small breakouts may resolve within a few months. Severe PIE from cystic acne or deep inflammation can persist for 12-24 months or longer without treatment. Vascular laser treatment can dramatically shorten this timeline but typically requires 2-4 sessions.
Both conditions improve with patience and consistency. The worst thing you can do is constantly switch products every few weeks looking for faster results. Choose a targeted routine, commit to it for at least 8-12 weeks, and assess progress objectively through comparison photos taken in consistent lighting.
References
- Bae-Harboe YS, Graber EM. "Easy as PIE (Postinflammatory Erythema)." The Journal of Clinical and Aesthetic Dermatology. 2013;6(9):46-47.
- Davis EC, Callender VD. "Postinflammatory hyperpigmentation: a review of the epidemiology, clinical features, and treatment options in skin of color." The Journal of Clinical and Aesthetic Dermatology. 2010;3(7):20-31.
- Desai SR, Alexis AF. "Post-inflammatory hyperpigmentation: clinical and treatment considerations." Journal of Drugs in Dermatology. 2018;17(6):659-664.
